JP Morgan 2025 Guide - Looking forward to the event. JP Morgan is AlzeCure Pharma's favorite event of the year, having the opportunity to meet great people and teams on joint interests, and becoming educated and inspired, as well as kicking of the year in a great way. Whether it’s your first JPM Week or your tenth, the below link provide you with the inside scoop to make the most of your time in San Francisco 2025, from sun-up to sundown. List of JPM Week 2025 Events: https://lnkd.in/eeHYPNJH Reach out to us at Alzecure to meet us at JP Morgan: info@alzecurepharma.com Martin Jönsson Johan Sandin
AlzeCure
Tillverkning av läkemedel
Stockholm, Stockholm County 6 797 följare
Developing groundbreaking treatments for Alzheimer’s disease, pain conditions and other severe CNS disorders. Learn more
Om oss
AlzeCure Pharma AB is a Swedish pharmaceutical company engaged in innovative drug research with a primary focus on Alzheimer’s disease. The company is listed on Nasdaq First North Premier Growth Market and is developing five drug candidates based on the two research platforms, NeuroRestore and Alzstatin. The NeuroRestore platform comprises symptom-relieving drug candidates while Alzstatin comprises disease modifying and preventive drug candidates. A diversified portfolio of drug candidates that act on central signaling pathways in the brain also opens up for other indications such as cognitive dysfunctions in traumatic brain injury (TBI), sleep apnea and Parkinson’s disease. The company also has a project in the field of pain in the early preclinical phase, TrkA-NAM. FNCA Sweden AB is the company’s certified adviser: contact +46(0)8-528 00 399, info@fnca.se. For further information, please visit our website at www.alzecurepharma.se.
- Webbplats
-
http://www.alzecurepharma.com
Extern länk för AlzeCure
- Bransch
- Tillverkning av läkemedel
- Företagsstorlek
- 11–50 anställda
- Huvudkontor
- Stockholm, Stockholm County
- Typ
- Publikt aktiebolag
- Grundat
- 2016
- Specialistområden
- Drug Discovery Research, Alzheimer's Disease, Neurodegenerative Diseases och Pain Management
Adresser
-
Primär
Hälsovägen 7
Stockholm, Stockholm County 14157, SE
Anställda på AlzeCure
Uppdateringar
-
JP Morgan 2025 Guide - Optimize Your Stay & Success Whether it’s your first JPM Week or your tenth, they provide you with the inside scoop to make the most of your time in San Francisco 2025, from sun-up to sundown. List of JPM Week 2025 Events: https://lnkd.in/eeHYPNJH Reach out to us at Alzecure to meet us at JP Morgan: info@alzecurepharma.com Martin Jönsson Johan Sandin AlzeCure Pharma #alzecure #neuroscience #alzstatin #neurorestore #ceo #jpm2025 #jpmorgan2025
-
Attending JP Morgan 2025 in San Francisco -January 13 – 16 Looking forward present AlzeCure Pharma & our ongoing projects in Alzheimer’s & pain, meeting with partners & investors. Reach out if you would like to meet up: info@alzecurepharma.com www.alzecurepharma.se/en The annual JP Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together industryleaders, emerging fast-growth companies, innovative technology creators, and members of the investment community. - Learn more at: https://lnkd.in/eZBPTdbM #alzecure #neurorestore #acd856 #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #painmanagement #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera
-
AlzeCure Pharma to present at Redeye Life Science Day - Tuesday, December 3 AlzeCure is participating at Redeye Life Science Day 2024 on December 3 at 13:00 CET, where CEO Martin Jönsson and CSO Johan Sandin willparticipate in a Q&A and answer questions about the latest developmentsand the company's plans going forward. Watch the livestream via https://lnkd.in/dA_bNAqr. Redeye Life Science Day 2024 - Venue: Sergelkonferensen, Mäster Samuelsgatan 42, Stockholm, Sweden - Time: 08:30 – 18:00 CET, December 3, 2024 - Even website & program: https://lnkd.in/dA_bNAqr To learn more: https://lnkd.in/dE9axuwB #alzecure #neurorestore #acd856 #Alzstatin#gammasecretasmodulator #alzheimer #dementia #neuroscience#alzheimerfonden #nordnet #avanza #erikpenserbank #redeye#aktiespararna #swedbank #analysguiden #finwire #placera
-
AlzeCure Pharma will present at the Pharma Outsourcing conference in Stockholm, Sweden, on December 3, 2024. AlzeCure is to present its collaboration and outsourcing strategy, from HTS to clinical phase phase 2 studies. The presentation will be held on December 3, at 2.10pm CET at Life City, by Karolinska Institutet in Stockholm. “Our outsourcing strategy has been based on strengthening the projects in areas where we have lacked certain skills or opportunities to carry out the work ourselves. We have successfully worked with different service providers in the various drug development stages and we will showcase how we have worked with outsourcing from discovery phase into clinical development,” said Dr. Forsell. Dr. Forsell has a PhD in Medical Biochemistry & Biophysics from Karolinska Institutet and more than 25 years of experience from several biotechnology and pharmaceutical companies, such as AstraZeneca, Orexo, and Merck in project and management positions. He is an expert in early drug development in the disease areas of neurology, pain and inflammation. For more information: https://lnkd.in/d4f6my88 #alzecure #biotechoutsoursing #biotech #placera #Avanza #Nordnet #redeye
-
AlzeCure Pharma to present at Redeye Life Science Day - Tuesday, December 3 AlzeCure is participating at Redeye Life Science Day 2024 on December 3 at 13:00 CET, where CEO Martin Jönsson and CSO Johan Sandin will participate in a Q&A and answer questions about the latest developments and the company's plans going forward. Watch the livestream via https://lnkd.in/dA_bNAqr. Redeye Life Science Day 2024 - Venue: Sergelkonferensen, Mäster Samuelsgatan 42, Stockholm, Sweden - Time: 08:30 – 18:00 CET, December 3, 2024 - Even website & program: https://lnkd.in/dA_bNAqr To learn more: https://lnkd.in/dE9axuwB #alzecure #neurorestore #acd856 #Alzstatin #gammasecretasmodulator #alzheimer #dementia #neuroscience #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera
-
AlzeCure presenterar på Pharma Outsourcing-konferensen i Stockholm AlzeCure Pharma kommer att presentera sin samarbets- och outsourcingstrategi i läkemedelsutvecklingsprocessen, från HTS till kliniska fas 2-studier. Presentationen hålls den 3 december klockan 14.10 på Life City, vid Karolinska Institutet i Stockholm. Konferensen arrangeras av Life Science Sweden. “Vår outsourcingstrategi har byggt på att stärka projekten inom områden där vi saknat viss kompetens eller möjligheter att själva utföra arbetet. Vi har framgångsrikt arbetat med olika tjänsteleverantörer i läkemedelsutvecklingsprocessen och vi kommer att visa hur vi har arbetat med outsourcing från tidig forskningsfas till klinisk utveckling”, säger Dr. Forsell. Mer om konferensen: https://lnkd.in/esg5y2FD #alzecure #swedenlifescience
-
AlzeCure Pharma presenterar på Stora Aktiedagarna 27 November kl 08:50 - Livesänt AlzeCures VD Martin Jönsson kommer presentera på Aktiespararnas Stora Aktiedagarna i Stockholm den 27 november kl 08:50. Martin kommer presentera bolagets projektportfölj, läkemedelskandidater samt planer inom de tre forskningsplattformarna NeuroRestore®, Alzstatin® och Painless, däribland den ledande läkemedelskandidaten ACD856 som förbereds för kliniska fas 2-studier. Presentationen följs av en Q&A som leds av Aktiespararnas moderator. Livesändningen finns tillgänglig via följande länk: https://lnkd.in/dQrBGKhM #alzecure #neurorestore #alztatin #aktiespararna #avanza #nordnet #swedbank #analysguiden #placera
-
Se intervjun om AlzeCures senaste kvartalsrapporten med CEO Martin Jönsson Martin berättar också om de senaste nyheterna och planerna. Till intervjun: https://lnkd.in/dVWV8Xdi #alzecure #neuroscience #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #zonda
-
AlzeCure Publicerar Delårsrapport - för januari - september 2024 ”Tredje kvartalet 2024 var ytterligare ett aktivt och positivt kvartal för AlzeCure Pharma. Under kvartalet publicerade och presenterade vi nya prekliniska resultat med TrkA-NAM ACD137, med positiva effekter i flera olika smärtmodeller, på den världsledande smärtkonferensen IASP. Vidare fick vi nya data antagna för presentation på Alzheimerkonferensen CTAD avseende vår kliniska kandidat NeuroRestore ACD856. Vi publicerade även en ny vetenskaplig artikel om NeuroRestore med fokus på behandling av Alzheimers. Genom en riktad emission fick vi dessutom in ytterligare kapital, knutet till emissionen som vi genomförde i maj.” Martin Jönsson, VD Läs mer: https://lnkd.in/dux8TZzb #alzecure #neuroscience #alzheimerfonden #nordnet #avanza #erikpenserbank #redeye #aktiespararna #swedbank #analysguiden #finwire #placera #zonda